breast hyperplasia
Conditions
Interventions
TREATMENT:Oral Danlu capsule placebo, 2.0 g/ time, 3 times/day. The total course of treatment was 8 During the menstrual period, the medication was stopped, and no anti-anxiety and depression drugs an
CONTROL:Oral Danlu capsule placebo 2.0 g/ time 3 times/day. The total course of treatment was 8 During the menstrual period the medication was stopped and no anti-anxiety and depression drugs and anal
Sponsors
Jiangsu Province Hospital of Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: A. Women over 18 years and under 65 years of age; B. conform to the western medical diagnostic criteria of breast hyperplasia; C. Hama score of 15-29 lasting for more than 2 weeks; D. Signed informed consent.
Exclusion criteria
Exclusion criteria: A. Patients with acute mastitis benign or malignant breast tumors or other breast-related diseases; B. Patients with a history of breast trauma or surgery; C. Patients with pancreatitis or other conditions causing chest pain; D. Pregnant or lactating women; E. Patients with severe cardiac hepatic or renal dysfunction (ALT AST = 1.5 × ULN); F. Patients with a known allergic constitution or hypersensitivity to any component of the study drugs; G. Patients with a prior confirmed diagnosis of anxiety or depression as re-evaluated by a board-certified psychiatrist specializing in brain disorders. Seventeen patients scored above 7 on the HAMD depression scale.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale Score;Improved Kupperman score;Serum stress-induced internal environment indicators;Chinese medicine symptom complex score;sex hormones; | — |
Countries
CHINA
Contacts
Public ContactYAO Chang
Jiangsu Province Hospital of Chinese Medicine
Outcome results
None listed